Khurum Khan - Concepedia

Author

Khurum Khan

Also Known As

K H Khan, K KHAN, K Khan, K. Khan, K.H. Khan, Kaainat Khan, Kamran Azeem Khan, Khurum H Khan, Khurum H. Khan, Khurum Hayat Khan

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

University College London Royal Marsden NHS Foundation Trust University College London Hospitals NHS Foundation Trust Institute of Cancer Research Royal Marsden Hospital

About

Khurum Khan is an author at University College London specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	572
2	Immunology	2	2	280
3	Public Health	1	1	16
4	Epidemiology	1	1	16
5	Otolaryngology	1	1	10

Khurum Khan

Publications

986

Citations

H-Index

Page 1

	Year	Citations
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer Andrew Woolston, Khurum Khan, Georgia Spain, Cancer Cell Tumor BiologyCetuximab Resistance LandscapeImmune Landscape EvolutionColorectal CancersMedicine	2019	254
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Sheela Rao, Marianne G. Guren, Khurum Khan, Annals of Oncology Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineSurgery	2021	230
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids Reyes Gonzalez-Exposito, Maria Semiannikova, B Griffiths, Journal for ImmunoTherapy of Cancer	2019	110
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management Khurum Khan, Mabel Wong, Karim Rihawi, The Oncologist	2016	62
Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience Khurum Khan, Clare Peckitt, Francesco Sclafani, BMC Cancer	2015	46
Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience Nalinie Joharatnam‐Hogan, Daniel Hochhauser, Kai‐Keen Shiu, Therapeutic Advances in Medical Oncology	2020	37
A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors. Khurum Khan, Li Yan, Janusz Mezynski, Journal of Clinical Oncology MedicineKras MutationMetronomic TherapyPharmacologyEscalation Study	2012	36
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Obbina Abani, Amr E. Abbas, Fatima Abbas, The Lancet Diabetes & Endocrinology	2023	34
Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer Andrew Woolston, Khurum Khan, Georgia Spain,	2018	26
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. Kai‐Keen Shiu, Yanrong Jiang, Mark Saunders, Journal of Clinical Oncology Surgical OncologyImmunologyPathologyNeoadjuvant PembrolizumabImmunotherapy	2024	26

Page 1